Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?— results of a study in 50 patients

Cremerius, U.; Wildberger, Joachim E.; Borchers, Holger; Zimny, M.; Jakse, G.; Günther, Rolf W.; Buell, Udalrich

doi:10.1016/s0090-4295(99)00272-1

Cited by 107 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of positron emission tomography (PET) with 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG) is currently under evaluation in urologic oncology [1][2][3][4][5][6][7][8][9]. Recent studies have shown that the uptake of [ 18 F]FDG is increased in many tumor entities compared to normal tissue [10,11].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Tsatalpas¹,

Beuthien‐Baumann

Kropp

et al. 2002

Urol Int

View full text Add to dashboard Cite

Introduction: The role of positron emission tomography (PET) with 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) is currently under evaluation in urologic oncology. The aim of the present study was to investigate the use of [¹⁸F]FDG positron emission tomography ([¹⁸F]FDG-PET) in the detection and treatment control of malignant germ cell tumors compared to computed tomography (CT). Materials and Methods: Thirty-two PET studies and CT scans were carried out in 23 patients with histologically proven germ cell tumors (10 seminomas, 12 non-seminomatous germ cell tumors (NSGCT), 1 unclassified serologic recurrent disease) Lugano stage I–III. The scans were done either after initial diagnosis (n = 21) and/or within 3–45 days after chemotherapy was completed (n = 11). PET and CT were validated either by histology (n = 7) or clinical follow-up of 6–11 months after the last PET study has been performed (n = 16). Sensitivity, specificity, accuracy, positive and negative predictive values were determined for PET and CT. Differences between PET and CT for parameters of diagnostic value were evaluated by χ² test. Results: Although not statistically significant, the sensitivity, accuracy and negative predictive value were higher for PET than for CT with respect to the detection of metastatic infradiaphragmatic and supradiaphragmatic lesions after initial diagnosis. The specificity and positive predictive value of PET and CT were comparable. After chemotherapy, PET was found to be significantly superior in specificity and accuracy compared to CT with respect to infradiaphragmatic lesions (p < 0.05). False-positive PET findings in supradiaphragmatic lesions after chemotherapy occurred in the case of inflammatory processes and resulted in a loss of specificity and accuracy compared to CT (p < 0.05). Conclusions: These preliminary results demonstrate [¹⁸F]FDG-PET to be a useful diagnostic tool for the initial staging and treatment control in patients with germ cell tumors. Possible advantages compared to CT, however, are as yet not clearly defined. The possibility of false-positive PET findings due to reactive supradiaphragmatic inflammatory processes early after chemotherapy have to be considered.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Tsatalpas¹,

Beuthien‐Baumann

Kropp

et al. 2002

Urol Int

View full text Add to dashboard Cite

show abstract

“…The results of the two studies mentioned above were assessed on the basis of histology or clinical follow–up. Cremerius et al [41]examined 50 patients and obtained comparable results for histopathologically proven GCT. In a direct comparison of CT and FDG–PET, the same research team found PET to have significant advantages in the evaluation of residual masses [42].…”

Section: Germ Cell Tumorsmentioning

confidence: 94%

Diagnosis and Monitoring of Urological Tumors Using Positron Emission Tomography

et al. 2001

View full text Add to dashboard Cite

“…Ultimately, 21 studies were excluded for undesirable article types (n=21), not written in English (n=6), and insufficient data (n=4), letter (n=2), case report (n=1), and review (n=8). Thus, 16 studies were included in our final dataset for the meta-analysis (Cremerius et al, 1998;Albers et al, 1999;Cremerius et al, 1999;Hain et al, 2000;Bokemeyer et al, 2002;Spermon et al, 2002;Tsatalpas et al, 2002;Lassen et al, 2003;De Santis et al, 2004;Becherer et al, 2005;de Wit et al, 2008;Hinz et al, 2008;Oechsle et al, 2008;Akbulut et al, 2011;Bachner et al, 2012;Siekiera et al, 2012). The flowchart of study selection was shown in Figure 1.…”

Section: Study Selection and Characteristics Of Studies In Our Analysismentioning

confidence: 99%

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Zhao

Ma²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?— results of a study in 50 patients

Cited by 107 publications

References 18 publications

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Diagnostic Value of <sup>18</sup>F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell Tumors

Diagnosis and Monitoring of Urological Tumors Using Positron Emission Tomography

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Contact Info

Product

Resources

About